Conquering Acute Respiratory Distress Syndrome ARDS and Cancer - Faron Pharmaceuticals

Endothelial barrier is everything

We all face life threatening conditions, if we lose the key property of vasculature - the endothelial barrier. Faron has identified several molecular mechanisms involved in the control of endothelial functions, providing opportunities to develop new unique drugs for true unmet medical need.

Read on ›
Drug development to save lives

Faron's lead drug platform Traumakine prevents vascular leakage through the injured endothelium of several central organs, potentially saving lives of seriously ill patients, e.g. those having acute respiratory distress syndrome (ARDS). The Clevegen project aims at recovering tumour immunity to help the host fight tumour growth and spread by controlling one of the key regulatory pathways connected to several cancers.

Read on ›
World-class expert network

Faron sources innovations from Academia and has built a strong expert network to execute drug development programs. The key opinion leaders play a crucial role in every step of our work, from inventions to clinical protocols and dissemination of results.

Read on ›
Many value inflection points in near future

Faron wants to create shareholder value, not only by advancing the pipeline but also by optimizing commercial steps of Faron products in various territories. Faron has already limited territorial licenses but retains all rights in Europe and USA for all proprietary drug candidates under development.

Read on ›

Lean Drug Development Company

Faron is a drug discovery and development company focussed on creating novel treatments for medical conditions with significant unmet needs. The company is based in Turku, Finland. Faron currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage.


TRAUMAKINE Phase III study targeting the treatment of ARDS

Faron has entered into pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). This study, called INTEREST, aims to achieve conditional European approval and has received €6 million European Union Framework Programme funding (FP7). Currently there is no available drug treatment for ARDS, an orphan lung disease which has a high 35-45% mortality rate.


Faron has moved to new premises within Turku Science Park

Faron is now located in the Intelligate II building in Turku Science Park. The building is LEED (Leadership in Energy & Environmental Design) certified for green leadership, saving money and resources. Our address is Joukahaisenkatu 6, next to the Kupittaa railway station. For visiting us, please use the lift of Intelligate I and press the button to the 6th Floor.

Recent news

Faron announced today a collaboration with the Turku PET Center, one of the largest centers in Europe, on the development of its novel cancer immunotherapy Clevegen.
€5 million equity investment made by A&B Ltd
Faron has received positive information on its pending patent applications related to serum CD73 measurements in patients suffering for ischemic conditions.


Careers in life saving drug development

We are currently recruiting experienced drug development individuals to complement the current Faron Team and its network.

See open positions here ›